Autolus Appoints Edgar Braendle as Chief Development Officer
On Thursday, July 15, Autolus announced (press release) the appointment of Edgar Braendle as Chief Development Officer (CDO). Below, Celltelligence provides insights on how Edgar Braendle’s vast oncology experience could accelerate the development and commercialization of Autolus’s lead asset, obe-cel (CD19 CAR-T, formerly AUTO1).
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.